2 completed, 1 recruiting, 1 terminated. 2 Phase 1, 2 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow dubermatinib: new trials by email Literature Review of dubermatinib trials Research Report on dubermatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia Azacitidine, Dubermatinib - Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia | Early Phase 1 | Completed | Uma Borate | 3 | 2020-11-05 | 2023-02-06 |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL TP-0903, TP-0903 and ibrutinib combination therapy - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 3 | 2019-06-10 | 2023-11-09 |
| First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors TP-0903 - Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer | Phase 1 | Completed | Sumitomo Pharma America, Inc. | 177 | 2016-12-14 | 2023-11-14 |
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis - Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Beat AML, LLC | 3000 | 2016-11-01 | 2026-09-03 |
Neoplasms (2) · Colorectal Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Ovarian Neoplasms (1) · Recurrence (1)
Sumitomo Pharma America, Inc. (2) · Beat AML, LLC (1) · Uma Borate (1)
United States (4)
Alice Mims, MD (1) · Phillip Komarnitsky (1) · Stephen P Anthony, DO (1) · Uma Borate, MD (1)